Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX10 + HLX04 versus sorafenib as first-line treatment for advanced or metastatic hepatocellular carcinoma
CTR20211154Phase 3Terminated
- Sponsor
- HyBioPharma
- Start
- Jun 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of serplulimab, HLX04-O, sorafenib in hepatocellular carcinoma (HCC), sponsored by HyBioPharma. Started Jun 2021; status: terminated.
02
Drugs
serplulimabHLX04-Osorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20211154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211154.